Paris-Based Lifeaz Raises €13M Funding To Democratise Defibrillator Access

The funding round was led by existing investor Mutuelles Impact a fund launched by La Mutualité Française and managed by XAnge in partnership with Impactivist (formerly Investir&+) with new participation from prominent investors including BNP Paribas, GO CAPITAL, and Mirova, an affiliate of Natixis.

Founded in 2015 by Johann Kalchman, Martial Itty, Timothée Soubise, and Jonathan Levy-Bencheton, Lifeaz’s mission is to empower everyone to save lives during cardiac emergencies. To this end, the startup developed Clark, the first defibrillator designed for home use, followed by a version tailored for businesses. Clark is designed in Paris and manufactured in Honfleur, Normandy.

Read Also - Lassie Raises $75M In Series C Round To Expand Pet Care Services In Europe

Lifeaz combines user-friendly design with connected technology, allowing remote monitoring and automatic daily self-tests to ensure the device is always ready in an emergency.

The company also offers comprehensive training programs via an app, video sessions, and in-person workshops so anyone can learn life-saving techniques and act with confidence. These initiatives work together to democratize access to defibrillators.

Lifeaz delivers its solutions through a turnkey rental model, which includes the defibrillator, connected maintenance, consumables replacement, and training.

With this new funding, Lifeaz plans to increase the number of lives saved from 100 to 1,000, grow its customer base from 25,000 to over 100,000, begin its European expansion, and strengthen its team with approximately 20 new hires in 2026.

During 2025–2026, EU-Startups has highlighted several significant funding rounds in hardware- and software-based cardiovascular HealthTech. Most recently, in January 2026, Bordeaux- and Tours-based FineHeart, a clinical-stage medical device company focused on cardiovascular technologies, completed the first closing of its €35 million Series C financing round.

In July 2025, Oxford-based Ultromics, an innovator in AI-driven cardiology diagnostics, raised €48 million through its Series C round. Meanwhile, in June 2025 Bordeaux-based DESKi secured €5.2 million in Seed funding to support the U.S. and global launch of its FDA-approved cardiac imaging software HeartFocus. Also in June 2025, Helsinki-based AIATELLA raised €2 million to scale its AI-powered cardiovascular imaging technology aiming to help prevent 100 million strokes.

Johann Kalchman, co-founder and CEO of Lifeaz, said, “Over the past ten years, Lifeaz has continuously demonstrated the need to democratize access to defibrillators. Our vision is that tomorrow, wherever you are, there will be a defibrillator less than one minute away and people who feel confident to step in and save a life whether at home, in a restaurant, a hotel, a gym, a medical practice or at work.

“This fundraising, therefore marks a major milestone: the renewed trust of our historical investors and the arrival of new leading partners now give us the means to scale. After more than 100 lives saved our ambition is clear: to multiply our impact by saving 1,000 lives within five years in France and across Europe.”